Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Stopped early

Conditions studied: Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration

In brief

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

Key facts

Study ID

NCT03699618

Run by

Johns Hopkins University

People needed

1

Starts

2019-05-29

Expected to finish

2020-01-06

Last updated by the study team

2020-02-19

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent and authorization of use and disclosure of protected health information
• Age 50 years or older
• Presence of subretinal hemorrhage (SRH) involving the fovea in patients with NVAMD including polypoidal choroidal vasculopathy (PCV)

You may not qualify if…

• SFH in the study eye due to causes other than NVAMD
• Media opacity due to concurrent vitreous hemorrhage or cataracts that preclude adequate imaging
• Substantial loss of VA due to condition other than AMD
• Limited visual potential from substantial atrophy or fibrosis in fovea
• Poor visual potential with known permanent reduction in visual acuity prior to SFH

Where it is running

• Wilmer Eye Institute, Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.